BioSpectrum ASIA EDITION
the business of Bio & Health Sciences

Thermo Fisher enables scalable gene therapy workflows

21 September 2021 | News

New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs

Addressing the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific has launched the integrated Gibco AAV-MAX Helper Free AAV Production System, a complete, optimized solution that simplifies the AAV vector production workflow.

The all-in-one AAV-MAX system increases productivity and cost efficiency by delivering high viral titers using Viral Production Cells 2.0, a new, clonally documented, 293F-derived mammalian cell line.

AAV is crucial to the field of gene therapy; more than 1,300 unique gene therapy products are currently under development, and nearly half are reliant on AAV. The ability to scale production is critical to bringing down costs and accelerating the process from research to commercialization.

The AAV-MAX system has been developed to scale from shake flasks to bioreactors. Coupled with the active development of regulatory-compliant** reagents, the system is designed to streamline the transition from research to commercial manufacturing. On average, the system can save viral vector researchers and developers 25 percent on plasmid DNA usage and 50 percent on production costs compared to polyethyleneimine (PEI)-based mammalian production systems. When used in conjunction with Thermo Fisher's expanded gene therapy portfolio of products,